ACD Pharma

ACD Pharma is a private Norwegian biotech firm at the forefront of bacteriophage therapeutics. It has successfully commercialized a product for aquaculture (Custus®YRS) and is translating its technological platform to address critical human health challenges, particularly antibiotic-resistant infections like Klebsiella pneumoniae. The company is strategically positioned with strong academic and clinical partnerships and is scaling manufacturing capabilities with a new facility in Lofoten, aiming to become a key player in the global fight against antimicrobial resistance.

Bacteriophage (phage) platform for isolating, characterizing, and formulating natural viruses that specifically target and kill pathogenic bacteria, as an alternative to antibiotics.

The phage therapy landscape is growing but still niche, with competitors ranging from small biotechs (e.g., Adaptive Phage Therapeutics, Locus Biosciences) to larger pharma exploring the modality. ACD Pharma differentiates itself with a commercially proven product in aquaculture, a dedicated manufacturing facility in development, and a strong focus on a specific WHO-critical pathogen (Klebsiella) through its Kleb-Gap consortium.